A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with or without aluminum adjuvant. A rapid and strong immune response was induced at day 14 after the first injection. The seroprotection rates ranged from 72.7% (95% confidence interval [CI], 62.7%-81.1%) for 5-mg wholevirion aluminum formulation to 97.0% (95% CI, 90.9%-99.7%) for 30-mg split-virion nonaluminum formulation. All formulations were well tolerated. The incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The 15-mg split-virion formulation had the best immunogenicity and safety. Trial Registration. ClinicalTrials.gov identifier: NCT00956111.
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In 2009, the emergent influenza A(H1N1) virus had caused the first pandemic influenza in the 21st century, as declared by the World Health Organization [1] . As of 31 December 2009, the H1N1 pandemic had killed at least 12,220 people around the world [2] . Unlike the previous 3 pandemics in the 20th century, the world had been actively preparing against a potential pandemic since 1997, when highly pathogenic H5N1 avian influ-enza first caused human fatality [3] . H5N1 vaccines with various formulations were developed as "prototype" vaccines, which aimed to elicit a satisfactory response to novel pandemic virus in immunologically naive humans by using less vaccine antigen [4] [5] . Because of the urgent need for vaccines against the 2009 H1N1 pandemic, the licensed prototype pandemic vaccines were fast-tracked into clinical trials. Some published results showed that a single dose of split-virion vaccine could elicit robust protective antibodies at day 21 after vaccination [6] [7] [8] . Here, on the basis of comparison of different dosages of candidate vaccines, we report that a fast seroprotective immune response can develop 14 days after vaccination.
Methods. Between 22 July and 7 September 2009, a doubleblind, randomized, controlled study was conducted at Huairou District, Beijing. The purpose of the study was to evaluate the immunogenicity and safety of different dosages of whole-virion and split-virion vaccines with or without aluminum adjuvant in healthy adults. The trial was registered with ClinicalTrials.gov (identifier NCT00956111) and approved by the ethical review committee of Beijing Centers for Disease Control and Prevention, in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. All participants gave their written informed consent.
A total of 706 healthy subjects from 18 to 60 years of age were enrolled in the study. The main exclusion criteria were cases or cured cases of A(H1N1) influenza or those in close contact with cases; allergies to eggs and vaccine ingredient; febrile or acute illness on the day of vaccination; history of chronic disease; treatment with cytotoxic or immunosuppressive drugs within the past 6 months; receipt of blood, bloodderived products, or any other vaccines within the past 3 months; current or planned attendance of any other clinical trials; and inability to comply with the visit schedule. Women volunteers who were lactating or planned to be pregnant in 60 days were excluded.
The vaccine strain X-179A, recommended by the World Health Organization (WHO) for the development of the influenza A(H1N1) vaccine [9] , was a reassortant between A/ California/07/2009 and A/PR/8/34. The vaccines used in this study were produced by Sinovac Biotech on a pilot scale in embryonated eggs as described elsewhere [10] . Because of the urgent need for evaluation of vaccine, the clinical trial started on 22 July 2009 before the WHO antigen reference was released. So the antigen content of vaccine was determined by the Temporary Antigen Reference developed and released by Chinese National Institute for the Control of Pharmaceutical and Biological Products (NIBPCP). After the WHO antigen reference was available at the end of July 2009, we recalibrated the antigen content of the tested vaccines and found that the difference between the NIBPCP references and WHO references was !10% that is within the acceptable test variation, suggesting that the dosage of our vaccines was accurate. Six formulations of influenza A(H1N1) vaccine and placebo were tested in the clinical trial: (1) 5-mg whole-virion with aluminum hydroxide, (2) 10-mg whole-virion vaccine with aluminum hydroxide, (3) 7.5-mg split-virion vaccine with aluminum hydroxide, (4) 15-mg split-virion vaccine with aluminum hydroxide, (5) 15-mg split-virion vaccine, (6) 30-mg split-virion vaccine, and (7) phosphate buffer saline as placebo control. The aluminum-adjuvanted formulation contained 0.3-0.6 mg/mL aluminum hydroxide. All formulas were free of preservatives. A randomization list was generated using SAS software, version 8.20, by a statistician who was not involved in the rest of the trial, and a randomized block design was used, with a block size of 1:1:1:1:1:1:1. The randomized vaccines and placebo were labeled with a code (sequential number A A001-A706) according to the randomization list. The labeled vaccines and placebo were identical in appearance and could only be identified with the sequential numbers. All eligible participants were given a randomized subject number and were vaccinated according to the numbers on the vaccine labels, which were the same as the randomized subject numbers. Both the vaccinators and investigators and the subjects were blinded to treatment assignment for the duration of the study. The randomization codes were revealed to the investigators and subjects on day 56 on completion of the study and when the statistician locked the database. The Data Safety Monitoring Board had access to the code for the interim code breaking and for the interim analysis on day 21.
The 706 adult subjects were randomly assigned to receive an intramuscul injection of one of the above mentioned blindlabeled formulations. The immunization regimen was 2 doses, 21 days apart. After injection, subjects were observed for immediate adverse events for 30 minutes. Diary cards were used to record the presence and intensity of adverse events over the next 3 days following vaccination. The subjects were also asked to report any unsolicited adverse events during the study period. Any adverse events reported by the subjects were reviewed and graded by investigators according to a standard scale [11] . Serum samples for the assessment of humoral immune response were collected on days 0, 14, 21, 35, and 42 and were assayed blindly by hemagglutination-inhibition (HI) assays as described elsewhere [10] .
Safety and immunogenicity were the coprimary end points. The frequency of adverse events was expressed in terms of the number and the proportion of individuals who had adverse events. The immunologic end points were adopted with the international seasonal influenza assessment criteria [12] , including postvaccination to prevaccination geometric mean titer (GMT) ratio, seroprotection rate (proportion with HI titer у1: 40) and seroconversion rate (proportion with prevaccination titer !1:10 and a postvaccination titer у1:40, or a proportion with prevaccination titer у1:10 and a у4-fold increase postvaccination). The following criteria should be met: GMT ratio 12.5; seroconversion rate у40%, seroprotection rate у70%.
The results of immunogenicity and safety were summarized with point estimates and 2-sided 95% CI. Pearson x 2 test or Fisher exact test were used to compare the number of subjects in groups when relevant. The logistic regression model was used to analyze the effects of dosage, aluminum adjuvant, and vaccine type (whole-virion or split-virion) on the rate of adverse events, seroconversion, and seroprotection The statistical analysis was conducted by an independent statistician. Statistical analysis was done by intension to treatment. The significance level was .05 (2-sided).
Results. From 22 to 25 July, 706 subjects were enrolled and randomly allocated to receive 1 of 7 treatments, with 100-102 per group. These subjects had an average age of 41.6 years. The age and gender were not statistically different in the 7 groups ( and .837, respectively) ( Table 1 ). All subjects received P p .964 the first dose, and 702 received the second dose. In total, 2, 2, and 1 subjects dropped out at days 14, 35, and 42, respectively. Thus, 706 vaccinated subjects were included in the safety assessment. Immunogenicity analysis included 706, 704, 704, 702, and 701 subjects on days 0, 14, 21, 35, and 42, respectively (Figure 1) .
The adverse reactions after the first inoculation are shown in Table 2 . Generally, all vaccine formulations were well tolerated without immediate allergic reactions or serious adverse events. A total of 87 (11.7%) recipients reported adverse reactions, and the incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The most frequently reported local events were pains at the injection site, and the most frequently reported systemic events were headache, myalgia, and malaise. The only case graded as severe was a 43-year-old woman who experienced an episode of myalgia that resolved within 72 h. Notably, the adverse events were most frequent in subjects receiving 10-mg whole-virion aluminum adjuvanted formulation, which was significantly higher than those receiving 15-mg splitvirion formulation ( ). However the Logistic regression P p .016 analysis showed that dosage, presence of aluminum adjuvant and type (whole-virion or split-virion) were not associated with the higher incidence of local and systemic adverse events (Tables  3 and 4) .
After the second inoculation, the adverse events were less frequent (30 [4.3%] of 704) and less severe than those after the first inoculation. Among 30 cases of adverse events, 29 cases were graded as mild, and only 1 subject who received 10-mg whole-virion aluminum vaccine reported transient symptom of moderate myalgia.
The results of HI assays are summarized in Table 5 . Before vaccination, there were no significant difference in baseline seroprotection rate ( ) and GMT ( ) between P p .856 P p .826 groups. Fourteen days after the first injection, HI antibody response was significantly induced by all study vaccines, meeting all 3 criteria for influenza vaccine [12] . The 30-mg and 15-mg split-virion vaccine elicited the highest GMT ratio, seroprotection rates, and seroconversion rates. The seroprotection rates were 96.0% and 97.0% in subjects receiving 15-mg or 30-mg split-viron vaccine, respectively. The strong immune response was also observed on day 21. The logistic regression suggested that higher seroprotection rates were associated with the absence of aluminum adjuvant and higher dosage vaccine ( for all comparisons) ( Table 6 ). By comparison, the P р .025 immune response was practically not observed in subjects who received placebo.
On day 35, although the second dose was delivered 1 week later, the split-virion vaccine showed better immunogenicity than other vaccine formulations. Although the seroconversion and seroprotection rates increased slightly in all vaccine groups from day 21 to day 35, the HI antibody GMT increased very little or even decreased. No evidence of boosting effect of the second inoculation was seen.
Discussion. Challenged by the outbreak of the pandemic influenza, we are facing the urgent situation to use the newly developed 2009 influenza A(H1N1) vaccines properly and wisely. Many 2009 influenza A(H1N1) vaccines had been evaluated in clinical trials. It had been reported that a single dose of 15-mg split-virion H1N1 vaccine could induce satisfactory immune response in adults 21 days after injection [6] [7] [8] . The same conclusion could be drawn from our research. A special feature of our study was that immunogenicity was evaluated on day 14. We found that the seroprotective immune response was elicited by all formulations as early as day 14, complying with all 3 criteria for the evaluation of seasonal influenza vaccine. The finding that the vaccine can provide seroprotection within 2 weeks is of particular importance for the emergent usage of vaccine to control pandemic influenza outbreak at present.
Another feature of this randomized and controlled study was that we tested the most formulations, which covered different dosage of whole-virion or split-virion vaccines, with or without aluminum adjuvant. The results showed that 15-mg split-virion vaccine induced the best immune response and the least adverse reaction among all tested vaccine formulations.
In the context of a pandemic, potential concurrent infection with the pandemic virus could be a powerful confounder for the immunogenic evaluation. Therefore, a placebo group is essential in such trials. Our findings showed that the subjects who received vaccine had robust antibody response, whereas the placebo group had practically no antibody response, suggesting that the immune response was induced by the tested vaccines but not concurrent infection of the H1N1 virus.
The logistic analysis in our report suggested that dosage, presence of aluminum adjuvant, and type of vaccine were not associated with the higher incidence of local and systemic adverse events. However, previous studies indicated that the aluminum adjuvant and higher antigen content was associated with higher rate of local reaction [7, 13] . The disagreement between different clinical trials warrants additional study.
The limitation in our study is that whole-virion vaccine without adjuvant was not included, and the tested dosage was not compared head-to-head. The reason was to reduce the sample size and accelerate the clinical process. This limitation, which might introduce bias in the logistical analysis regarding seroprotection and adverse events, remains to be explored further. However, the goal of the study-to find the best vaccine formulation against the 2009 influenza A(H1N1) virus among the candidates-has been achieved.
